Aastha Pal

Keywords adoptive T cell therapy JAK/STAT common gamma chain IL-9 IL-9R cancer immunotherapy cytokines cell signaling CAR T cell therapy TCR T cell therapy Introduction Common γ-chain (γc) cytokines are critical regulators of T cell differentiation and function, exerting their effects through JAK/STAT signaling pathways.1 Their potential to enhance adoptive T cell therapy for cancer has long been recognized.2 Building on an orthogonal interleukin (IL)-2 system in which we swapped...

Protein production DNA encoding mouse and human IL-2 and IL-9, and mouse IL-9Q115T were cloned into the mammalian expression vector pD649, which includes a C-terminal 8xHis tag for affinity purification. DNA encoding mouse serum albumin (MSA) was purchased from Integrated DNA Technologies (IDT) and cloned into pD649 as an N-terminal fusion.

Abstract The FDA approval of T cell receptor-engineered T cells (TCR-T) for synovial sarcoma demonstrates the potential for adoptive T cell therapies (ACTs) in solid tumors. However, the paucity of tumor-specific targets without expression in normal tissues remains a major bottleneck, especially in rare cancer subtypes.